{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-24-000012","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.092117+00:00","generated_at":"2026-06-05T06:53:38.210998+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M","bullets":["Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.","Positive Phase 1A/B SL-172154 data in HR-MDS and TP53m AML; completed initial enrollment for expansion cohorts.","Completed Phase 1B SL-172154 + PLD trial in PROC with positive interim data; all mid-2024 updates expected.","Strategic collaboration with Ono Pharma for autoimmune targets; up to $227M in milestones plus tiered royalties.","Completed $50M public offering in Q4 2023; cash runway extended into 2026 beyond Phase 1 readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-24-000012","json":"https://secwatch.observer/filing/0001680367-24-000012.json","markdown":"https://secwatch.observer/filing/0001680367-24-000012.md","text":"https://secwatch.observer/filing/0001680367-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000012/0001680367-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000012/sttk-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:53:38.210998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"846a3bd3adc2e3065a980ffd1208451d1a396463","claim":"Shattuck Labs, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680367/000168036724000012/0001680367-24-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}